Episodes (Page 3)
✨
Improving communication and teamwork in the OR.
Hans Arora
✨
HoLEP adoption strategies and patient selection.
Daniel S. Kellner
✨
Dr. Flannigan presented phase 2 data for ST-01, a lidocaine solution for chronic scrotal pain.
Ryan Flannigan, MD
✨
Dr. Nima Almassi discusses long-term data for bladder preservation in muscle-invasive bladder cancer.
Nima Almassi, MD
✨
Sasha Vereecken explains how urodynamics advanced reconstructive urology.
Sasha Vereecken, BScN, RN
✨
Drs. Amy Pearlman and Andrew Cohen discuss managing patient expectations.
Amy Pearlman, MD
✨
Dr. Narmina Khanmammadova presents interim findings on pelvic floor therapy before HoLEP.
Narmina Khanmammadova, MD
✨
Dr. Jessica Yih reviews evidence for testosterone therapy in women.
Jessica Yih, MD
✨
Dr. Nally discusses decision regret and toxicity perception in RCC patients.
Elizabeth Nally, MBBS
✨
BCG maintenance therapy's importance in NMIBC is discussed.
✨
History of the belief that testosterone drives prostate cancer explored.
Abraham Morgentaler, MD
✨
Wearable technology's potential in sexual health is explored.
Elliot Justin
✨
Key phase 3 advances in prostate cancer practice changes highlighted.
Alan Bryce, MD
✨
Rising incidence of young-onset bladder cancer is examined.
Gabriela Diaz, MD
Laura Bukavina, MD
✨
Integrating emerging molecular biomarkers into clinical practice discussed.
Joshua Lang, MD, MS
✨
Prostate cancer diagnosis and patient advocacy are discussed.
Gabe Canales
✨
EV/pembrolizumab redefines the MIBC treatment paradigm.
Matthew Galsky, MD
✨
Phase 1 data on darlifarnib plus cabozantinib presented.
Adanma Ayanambakkam, MD
✨
Clinical role and accuracy of mail-in semen analysis reviewed.
Joshua Halpern, MD, MS
✨
Optimizing patient follow-up systems in urologic oncology.